OS Therapies Inc
OST-HER2
osteosarcoma
Countdown
86days
Approval decision · ~ Sep 30, 2026 estimated
What's at stake
A final FDA approval decision on OST-HER2 for osteosarcoma is expected ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 11h ago
“The Company anticipates a potential CMA decision by EMA in the fourth quarter of 2026.”